title: Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
abstract: OBJECTIVE
  To study the effectiveness and safety of combined standard-dosed Solifenacin and Trospium for management of symptoms of overactive bladder (OAB) in elderly patients after the treatment with Tamsulosin.
  
  
  METHODS
  A total of 417 men over 50 years of age (average age 57.9 (8.3)) with diagnosed prostatic obstruction (score 8-19 according to I-PSS), who had not taken Tamsulosin before, were enrolled in the study. I-PSS questionnaire (from 8 to 19 - moderate) and Awareness Tool questionnaire for evaluating OAB symptoms (total score for OAB symptoms over 8) were used at the beginning and at the end of the observation. Also, urodynamic parameters were examined.
  
  
  RESULTS
  Percentage of patients with prevalent symptoms of obstruction of urethra decreases after the treatment with Tamsulosin and then rises again (36.2%), but absolute number of patients remains smaller than initial data. Percentage of patients with relative prevalence of symptoms of overactive bladder slightly increases against administration of Tamsulosin and reaches initial values at the time of administration of anti-muscarinic drugs with absolute decrease in number of such patients.
  
  
  CONCLUSIONS
  Combination of Trospium and Solifenacin is an effective way to manage residual symptoms of hyperactive bladder during treatment of early obstruction of urinary bladder.
authors.affiliation: Department of Social Sciences, Far Eastern Federal University , Vladivostok , RUVVO Russian Federation .
authors.forename: Kirill
authors.initials: K
authors.lastname: Kosilov
authors.forename: Sergey
authors.initials: S
authors.lastname: Loparev
authors.forename: Marina
authors.initials: M
authors.lastname: Ivanovskaya
authors.forename: Liliya
authors.initials: L
authors.lastname: Kosilova
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D001561:Benzilates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009662:Nortropanes / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D001561:Benzilates; D018727:Muscarinic Antagonists; D009662:Nortropanes; D013449:Sulfonamides; C003330:trospium chloride; D000077409:Tamsulosin; D000069464:Solifenacin Succinate
keywords: Anti-muscarinic; overactive bladder; prostate; tamsulosin